Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ucb ADR (OP: UCBJY )

98.11 -0.39 (-0.40%)
Streaming Delayed Price Updated: 3:37 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102,733
Open 98.18
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 98.50
Today's Range 97.63 - 98.49
52wk Range 56.77 - 106.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders
UCB's Bimzelx shows sustained efficacy in psoriasis and hidradenitis suppurativa, with high skin clearance rates and improved symptoms over long-term trials. 
Via Benzinga
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. 
Via Benzinga

Performance

YTD
+0.44%
+0.44%
1 Month
+0.19%
+0.19%
3 Month
+3.18%
+3.18%
6 Month
+8.49%
+8.49%
1 Year
+67.54%
+67.54%

More News

Read More
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
Via Benzinga
Exposures Product Safety
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
Via Benzinga
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
Via Benzinga
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
Via Benzinga
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
Via Talk Markets
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Via Benzinga
Exposures Product Safety
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
Via Benzinga
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Via Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Via Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
Via Benzinga
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
Via Benzinga
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Via Benzinga
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Via Benzinga
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
Via Benzinga
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
Via Talk Markets
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Via Benzinga
UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
Via Benzinga
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
Via Benzinga
UCB Gets EU Approval For Bimekizumab In Psoriasis
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 9, 2021
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.